Galectin-3 in patients undergoing ablation of atrial fibrillation

Galectin-3 in patients undergoing ablation of atrial fibrillation
复制标题

DOI:
10.1016/j.ijcme.2014.10.003
复制
发表时间:
2014-11-01
期刊:
IJC METABOLIC & ENDOCRINE
影响因子:
--
通讯作者:
Babuty, Dominique
Babuty, Dominique
中科院分区:
其他
文献类型:
--
作者:
Clementy, Nicolas;Piver, Eric;Babuty, Dominique

文献摘要

被引文献

相似文献

背景:房颤的维持机制包括纤维化。半凝集素-3作为纤维化的生物标志物,可能是心房重构的一个有价值的标志物。我们试图发现心房颤动患者的临床特征与较高的半凝集素-3水平之间是否存在联系。方法:对房颤消融治疗的连续患者进行血清半乳糖凝集素-3浓度测定。结果:纳入187例患者,56%为阵发性心房颤动。半凝集素-3平均浓度为14.5 +/- 5.5 ng/mL。年龄、持续性房颤、潜在心脏病、心力衰竭、左室射血分数(LVEF)下降、高血压、糖尿病、ACEI/ARB治疗、左心房扩大和肾功能不全与半乳糖凝集素-3水平升高相关。重要的是,持续性房颤、女性和LVEF = 15 ng/mL)。结论:持续性房颤是高半乳糖凝集素-3浓度的独立预测因子。这种纤维化的生物标志物可能暗示心房重构和房颤维持的机制,从而有助于房颤患者治疗策略的设计。(C) 2014年作者。爱思唯尔爱尔兰有限公司出版。这是一篇基于CC BY-NC-ND许可的开放获取文章
Background: Mechanisms of maintenance of atrial fibrillation are known to include fibrosis. Galectin-3, as a biomarker of fibrosis, may be a valuable marker of atrial remodeling. We sought to find whether there was a link between clinical features and higher galectin-3 levels in patients with atrial fibrillation.Methods: Serum concentrations of Galectin-3 were determined in a consecutive series of patients addressed for ablation of atrial fibrillation.Results: One-hundred-and-eighty-seven patients were included, 56% having a paroxysmal type of atrial fibrillation. Mean Galectin-3 concentration was 14.5 +/- 5.5 ng/mL. Age, persistent form of atrial fibrillation, underlying cardiac disease, heart failure, decreased left ventricular ejection fraction (LVEF), hypertension, diabetes, treatment with ACEI/ARB, enlarged left atrium and renal insufficiency were associated with higher Galectin-3 levels. Importantly, persistent form of atrial fibrillation, female sex, and LVEF = 15 ng/mL).Conclusions: Persistent type of atrial fibrillation is an independent predictor of higher Galectin-3 concentration. This biomarker of fibrosismay be implied in the mechanisms of atrial remodeling and maintenance of atrial fibrillation, and thus be helpful for the design of therapeutic strategy in patients with atrial fibrillation. (C) 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license